多参数磁共振成像在主动监测中Grade Group 1前列腺癌风险分层中的应用
该回顾性研究基于约翰霍普金斯主动监测注册数据库,评估mpMRI adoption后对Grade Group 1前列腺癌隐匿高级别病变识别的改善。研究纳入2013年后接受单次mpMRI的男性(阴性mpMRI 225例,PI-RADS≥3 207例),并与2013年前未使用mpMRI时代的669例比较。结果显示阴性mpMRI组升级风险显著低于未使用mpMRI时代组(HR 0.61),而PI-RADS≥3组升级风险显著高于未使用mpMRI时代组(HR 1.96)。
要点
- mpMRI阴性者2年及4年无升级生存率分别为93%和83%,显著优于未使用mpMRI时代组。
- PI-RADS≥3者2年及4年无升级生存率分别为74%和59%,升级风险显著增高。
- mpMRI有助于优化主动监测的入组和监测决策。
核心结论
- mpMRI改善了主动监测中Grade Group 1前列腺癌患者的风险分层,应辅助入组和监测决策。
研究设计与样本
- 回顾性队列研究,从约翰霍普金斯主动监测注册数据库纳入2013年后注册的Grade Group 1前列腺癌男性,接受单次mpMRI,分为阴性mpMRI组(n=225)和PI-RADS≥3组(n=207),并与2013年前未使用mpMRI时代组(n=669)比较。
主要发现
- 阴性mpMRI组、PI-RADS≥3组和未使用mpMRI时代组的2年无升级生存率分别为93%、74%和87%,4年分别为83%、59%和76%(P < 0.001)。
- 多变量分析中,与未使用mpMRI时代组相比,阴性mpMRI组升级风险显著降低(HR 0.61,95%CI 0.39-0.95,P=0.03),PI-RADS≥3组升级风险显著增高(HR 1.96,95%CI 1.36-2.82,P < 0.001)。
临床怎么用
- 在主动监测入组和随访中,可使用mpMRI对Grade Group 1前列腺癌患者进行风险分层,阴性者升级风险较低,PI-RADS≥3者升级风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess if the adoption of multiparametric magnetic resonance imaging (mpMRI) in active surveillance (AS) has improved the identification of occult higher-grade prostate cancer (PCa). PATIENTS AND METHODS: We retrospectively identified men from the Johns Hopkins AS registry enrolled since 2013 (year of mpMRI adoption) with Grade Group (GG) 1 PCa and who underwent a single mpMRI. Men in this group were dichotomised by the presence (n = 207) or absence (negative mpMRI, n = 225) of one or more lesions with a Prostate Imaging-Reporting and Data System (PI-RADS) score of ≥ 3. Both groups were compared to a third cohort of men with GG1 PCa enrolled in AS prior to 2013 (pre-mpMRI era, n = 669). The risk of upgrading to GG ≥ 2 PCa on follow-up biopsies (performed with or without MRI targeting) was evaluated among the groups using survival analysis. RESULTS: Men in both mpMRI groups underwent a median (interquartile range [IQR]) of 2 (2-3) biopsies separated by a median (IQR) interval of 13 (12-16) months, whereas men in the pre-MRI era underwent a median (IQR) of 3 (2-5) biopsies, separated by a median (IQR) interval of 12 (12-14) months. The 2- and 4-year upgrade-free survival rates were 93% and 83%, 74% and 59%; and, 87% and 76% for the negative mpMRI, PI-RADS ≥ 3, and pre-mpMRI-era groups, respectively (P < 0.001). On multivariable analysis, both mpMRI groups had significantly different risk of upgrading compared to pre-mpMRI-era group (negative mpMRI group: hazard ratio [HR] 0.61, 95% confidence interval [CI] 0.39-0.95, P = 0.03; PI-RADS ≥ 3 group: HR 1.96, 95% CI 1.36-2.82, P < 0.001). CONCLUSIONS: mpMRI improves the risk stratification of men on AS and should be used to aid enrolment and monitoring decisions.
引用
- Mamawala MK, Meyer AR, Landis PK, et al. Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance. BJU Int. 2020. PMID: 32039537. doi:10.1111/bju.15033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。